---
figid: PMC4142049__nihms-517393-f0003
figtitle: LOX-1 signaling mechanistically links atherosclerosis, hypertension, and
  diabetes
organisms:
- Mus musculus
- Rattus norvegicus
- Candida dubliniensis
- Salvia miltiorrhiza
- Homo sapiens
- Oryctolagus cuniculus
- Human betaherpesvirus 5
- Corynephage beta
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Oryctolagus cuniculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC4142049
filename: nihms-517393-f0003.jpg
figlink: /pmc/articles/PMC4142049/figure/F3/
number: F3
caption: 'LOX-1 signaling mechanistically links atherosclerosis, hypertension, and
  diabetes. oxLDL binding to LOX-1 affects NO catabolism by two mechanisms: (1) increased
  ROS production, which not only reacts with intracellular NO, resulting in the formation
  of cytotoxic peroxynitrite (ONOO–) but also down-regulates eNOS, thereby decreasing
  NO bioavailability; (2) oxLDL, through LOX-1 receptor activates arginase II, competing
  with eNOS for use of the substrate l-arginine, thus, down-regulating NO formation,
  and contributing to vascular dysfunction. Persistently increased ROS can activate
  multiple signaling pathways within vascular cells, such as PI3K/Akt, MAPK (p38,
  ERK and JNK), PKA, PKC, PTK, and p66Shc. These pathways further activate the redox-sensitive
  NF-κB pathway, increase NF-κB binding to LOX-1 promoter, and orchestrate LOX-1 expression
  in atherosclerosis. Alternatively, SIRT1 deacetylates NF-κB to suppress the expression
  of LOX-1. LOX-1 is also the target gene of other transcription factors, such as
  AP-1, Oct-1, and PPAR-γ. AGEs act as a ligand of LOX-1 and can upregulate LOX-1
  expression via PI3K/mTORC2/Akt pathway. In light of the cross-talk between AT1R
  and LOX-1, and potentially between RAGE and LOX-1, LOX-1 may provide a mechanistic
  link between atherosclerosis, hypertension, and diabetes. Ang-II angiotensin-II,
  oxLDL oxidized LDL, AGEs advanced glycation end-products, AT1R Ang-II type 1 receptor,
  RAGE receptor of advanced glycation end-products, NO nitric oxide, eNOS endothelial
  NO synthase, SIRT1 sirtuin-1, mTORC2 mammalian target of rapamycin complex 2, PI3K
  phosphatidylinositol 3-kinases, MAPK mitogen-activated protein kinases, ERK extracellular
  regulated protein kinases, JNK c-Jun N-terminal kinase, PKA protein kinase A, PKC
  protein kinase C, PTK protein tyrosine kinase, p66Shc 66-kDa isoform of Shc adaptor
  proteins, NF-κB nuclear factor-kappa B, AP-1 activator protein-1, Oct-1 octamer-binding
  protein 1, PPAR-γ peroxisome proliferator-activated receptor-gamma'
papertitle: 'LOX-1 in atherosclerosis: biological functions and pharmacological modifiers.'
reftext: Suowen Xu, et al. Cell Mol Life Sci. ;70(16):2859-2872.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9519089
figid_alias: PMC4142049__F3
figtype: Figure
redirect_from: /figures/PMC4142049__F3
ndex: d5f352aa-dee2-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4142049__nihms-517393-f0003.html
  '@type': Dataset
  description: 'LOX-1 signaling mechanistically links atherosclerosis, hypertension,
    and diabetes. oxLDL binding to LOX-1 affects NO catabolism by two mechanisms:
    (1) increased ROS production, which not only reacts with intracellular NO, resulting
    in the formation of cytotoxic peroxynitrite (ONOO–) but also down-regulates eNOS,
    thereby decreasing NO bioavailability; (2) oxLDL, through LOX-1 receptor activates
    arginase II, competing with eNOS for use of the substrate l-arginine, thus, down-regulating
    NO formation, and contributing to vascular dysfunction. Persistently increased
    ROS can activate multiple signaling pathways within vascular cells, such as PI3K/Akt,
    MAPK (p38, ERK and JNK), PKA, PKC, PTK, and p66Shc. These pathways further activate
    the redox-sensitive NF-κB pathway, increase NF-κB binding to LOX-1 promoter, and
    orchestrate LOX-1 expression in atherosclerosis. Alternatively, SIRT1 deacetylates
    NF-κB to suppress the expression of LOX-1. LOX-1 is also the target gene of other
    transcription factors, such as AP-1, Oct-1, and PPAR-γ. AGEs act as a ligand of
    LOX-1 and can upregulate LOX-1 expression via PI3K/mTORC2/Akt pathway. In light
    of the cross-talk between AT1R and LOX-1, and potentially between RAGE and LOX-1,
    LOX-1 may provide a mechanistic link between atherosclerosis, hypertension, and
    diabetes. Ang-II angiotensin-II, oxLDL oxidized LDL, AGEs advanced glycation end-products,
    AT1R Ang-II type 1 receptor, RAGE receptor of advanced glycation end-products,
    NO nitric oxide, eNOS endothelial NO synthase, SIRT1 sirtuin-1, mTORC2 mammalian
    target of rapamycin complex 2, PI3K phosphatidylinositol 3-kinases, MAPK mitogen-activated
    protein kinases, ERK extracellular regulated protein kinases, JNK c-Jun N-terminal
    kinase, PKA protein kinase A, PKC protein kinase C, PTK protein tyrosine kinase,
    p66Shc 66-kDa isoform of Shc adaptor proteins, NF-κB nuclear factor-kappa B, AP-1
    activator protein-1, Oct-1 octamer-binding protein 1, PPAR-γ peroxisome proliferator-activated
    receptor-gamma'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Lepr
  - Angpt2
  - Ager
  - Mok
  - Ar
  - Olr1
  - Pik3r1
  - Mtor
  - C2
  - Mapk8
  - Ephb2
  - Mapk1
  - Crk
  - Grap2
  - Syp
  - Mapk14
  - Ahsa1
  - Shc1
  - Rictor
  - Akt1
  - Nfkb1
  - Nos3
  - Sirt1
  - Jun
  - Pou2f1
  - Prkcg
  - Pik3cg
  - Ephb1
  - Slc22a1
  - AR
  - OLR1
  - MTOR
  - RICTOR
  - NOS3
  - SIRT1
  - JUN
  - SLC22A1
  - ANGPT2
  - VPS51
  - AGER
  - MOK
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - PRRT2
  - PRKCA
  - PRKCB
  - PRKCD
  - PRKCE
  - PRKCG
  - PRKCH
  - PRKCI
  - PRKCQ
  - PRKCZ
  - PRKD3
  - PTK2B
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAPKAP1
  - MLST8
  - EPHB2
  - CRK
  - AIMP2
  - GRAP2
  - AHSA1
  - POLDIP2
  - AKT1
  - AKT2
  - AKT3
  - NFKB1
  - ENO4
  - FOS
  - FOSB
  - JUNB
  - JUND
  - POU2F1
  - ar
  - MKP-4
  - p38b
  - rl
  - Pka-C1
  - Pka-R2
  - Pka-C3
  - Pka-R1
  - Pka-C2
  - inaC
  - Pkc98E
  - aPKC
  - Pkc53E
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Tor
  - bsk
  - Erk7
  - lic
  - Nurf-38
  - Ebp
  - p38a
  - Hrb87F
  - p38c
  - rictor
  - Akt
  - Dif
  - dl
  - Rel
  - AP-1gamma
  - Jra
  - kay
  - nub
  - Cancer
---
